| Date | Panel | Item | Activity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacogenomics_Paediatric v0.49 | CYP2C19 | Zornitza Stark Publications for gene: CYP2C19 were set to 27981572 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.36 | CYP2C19 | Zornitza Stark Marked gene: CYP2C19 as ready | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.36 | CYP2C19 | Zornitza Stark Gene: cyp2c19 has been classified as Green List (High Evidence). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.36 | CYP2C19 | Zornitza Stark Phenotypes for gene: CYP2C19 were changed from to Voriconazole | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.35 | CYP2C19 | Zornitza Stark Classified gene: CYP2C19 as Green List (high evidence) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.35 | CYP2C19 | Zornitza Stark Gene: cyp2c19 has been classified as Green List (High Evidence). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.34 | CYP2C19 | Zornitza Stark reviewed gene: CYP2C19: Rating: GREEN; Mode of pathogenicity: None; Publications: 27981572, 26616742, 31549386; Phenotypes: Voriconazole; Mode of inheritance: None | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.33 | CYP2C19 |
David Metz changed review comment from: (27981572) Voriconazole, moderate strength. Poor metabolizer: "Higher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events." Ultrarapid metabolizer: "probability of attainment of therapeutic voriconazole concentrations is small with standard dosing." (23698643) Clopidogrel, strong recommendation (though only shown in adult acute coronary syndrome / percutaneous coronary intervention). Poor metabolizer: Significantly reduced platelet inhibition; increased residual platelet aggregation; increased risk for adverse cardiovascular events. Sources: Other; to: (27981572) Voriconazole, moderate strength. Poor metabolizer: "Higher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events." Ultrarapid metabolizer: "probability of attainment of therapeutic voriconazole concentrations is small with standard dosing." |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.33 | CYP2C19 |
David Metz changed review comment from: Voriconazole: Improved time to target concentration with genotype directed dosing (PMID 26616742). Voriconazole: Increased success cf. historical controls (PMID 31549386); to: Voriconazole: Improved time to target concentration with genotype directed dosing (PMID 26616742), reduced underexposure (PMID: 31549389) (PMID 31549386) |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.33 | CYP2C19 |
David Metz changed review comment from: Improved time to target concentration with genotype directed dosing (PMID 26616742). Increased success cf. historical controls (PMID 31549386); to: Voriconazole: Improved time to target concentration with genotype directed dosing (PMID 26616742). Voriconazole: Increased success cf. historical controls (PMID 31549386) |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.33 | CYP2C19 |
David Metz changed review comment from: Improved time to target concentration with genotype directed dosing (PMID 26616742); to: Improved time to target concentration with genotype directed dosing (PMID 26616742). Increased success cf. historical controls (PMID 31549386) |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.33 | CYP2C19 | David Metz edited their review of gene: CYP2C19: Added comment: Improved time to target concentration with genotype directed dosing (PMID 26616742); Changed publications: 27981572, 26616742 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.33 | CYP2C19 |
David Metz changed review comment from: (27981572) Voriconazole, moderate level evidence. Poor metabolizer: "Higher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events." Ultrarapid metabolizer: "probability of attainment of therapeutic voriconazole concentrations is small with standard dosing." (23698643) Clopidogrel, strong evidence (though only shown in adult acute coronary syndrome / percutaneous coronary intervention). Poor metabolizer: Significantly reduced platelet inhibition; increased residual platelet aggregation; increased risk for adverse cardiovascular events. Sources: Other; to: (27981572) Voriconazole, moderate strength. Poor metabolizer: "Higher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events." Ultrarapid metabolizer: "probability of attainment of therapeutic voriconazole concentrations is small with standard dosing." (23698643) Clopidogrel, strong recommendation (though only shown in adult acute coronary syndrome / percutaneous coronary intervention). Poor metabolizer: Significantly reduced platelet inhibition; increased residual platelet aggregation; increased risk for adverse cardiovascular events. Sources: Other |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.33 | CYP2C19 |
David Metz gene: CYP2C19 was added gene: CYP2C19 was added to Pharmacogenomics_Paediatric. Sources: Other Mode of inheritance for gene: CYP2C19 was set to Other Publications for gene: CYP2C19 were set to 27981572 Added comment: (27981572) Voriconazole, moderate level evidence. Poor metabolizer: "Higher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events." Ultrarapid metabolizer: "probability of attainment of therapeutic voriconazole concentrations is small with standard dosing." (23698643) Clopidogrel, strong evidence (though only shown in adult acute coronary syndrome / percutaneous coronary intervention). Poor metabolizer: Significantly reduced platelet inhibition; increased residual platelet aggregation; increased risk for adverse cardiovascular events. Sources: Other |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||